Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders

Abstract

Melatonin is a physiological hormone involved in sleep timing and is currently used exogenously in the treatment of primary and secondary sleep disorders with empirical evidence of efficacy, but very little evidence from randomised, controlled studies. The aim of this meta-analysis was to assess the evidence base for the therapeutic effects of exogenous melatonin in treating primary sleep disorders. An electronic literature review search of MEDLINE (1950-present) EMBASE (1980- present), PsycINFO (1987- present), and SCOPUS (1990- present), along with a hand-searching of key journals was performed in July 2013 and then again in May 2015. This identified all studies that compared the effect of exogenous melatonin and placebo in patients with primary insomnia, delayed sleep phase syndrome, Non 24- hour sleep wake syndrome in people who are blind, and REM-Behaviour Disorder. Meta-analyses were performed to determine the effect of magnitude in studies of melatonin in improving sleep. A total of 5030 studies were identified; of these citations, 13 were included for review based on the inclusion criteria of being: double or single-blind, randomised and controlled. Results from the meta-analyses showed the most convincing evidence for exogenous melatonin use was in reducing sleep onset latency in primary insomnia (p=0.002), delayed sleep phase syndrome (p<0.0001), and regulating the sleepwake patterns in blind patients compared with placebo. These findings highlight the potential importance of melatonin in treating certain first degree sleep disorders. The development of large-scale, randomised, controlled trials is recommended to provide further evidence for therapeutic use of melatonin in a variety of sleep difficulties

Nanoplastics Cause Neurobehavioral Impairments, Reproductive and Oxidative Damages, and Biomarker Responses in Zebrafish: Throwing up Alarms of Wide Spread Health Risk of Exposure

“…After seven weeks of PS-NPs exposure, the dysregulation of circadian rhythm locomotion activity was shown by the treated fish group and might be related to the melatonin, a key hormone controlling the circadian rhythm. Generally, this physiological hormone gets involved in sleep timing and currently used as a primary treatment for sleep disorders in humans [109]. Melatonin has also been reported to promote sleep-like behavior in diurnal vertebrates, such as zebrafish, and is responsible for other physiological processes, including immune function, blood pressure, and retinal physiology [110,111].…”

Genetic studies of accelerometer-based sleep measures in 85,670 individuals yield new insights into human sleep behaviour

“…Furthermore, serotonin is synthesized by the pineal gland as a processing step for melatonin production, a key hormone in circadian rhythm regulation and sleep timing. Melatonin is frequently taken as a dietary supplement in the United States with its use more than doubling between 2007 and 2012 48 , although clinical trial results for sleep and circadian rhythm disorders are mixed 49 . In addition, excess melatonin levels can also lead to disturbed sleeping and other health issues with the American Academy of Sleep Medicine recommending avoiding melatonin for chronic insomnia 50 .…”

Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammation

“…Melatonin is a major hormone molecular product released from the pineal gland into the circulatory system to regulate the immune system and circadian rhythms …”